Mebendazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Mebendazole: From Parasitic Infections (Anthelmintic) to Acne
One-Sentence Summary
Mebendazole is a benzimidazole anthelmintic, traditionally used to treat parasitic worm infections by inhibiting parasite β-tubulin polymerization and glucose uptake. The TxGNN model predicts it may be effective for Acne, but this is currently supported by 0 clinical trials and only 1 tangentially related case report, with no known mechanistic basis connecting the drug's antiparasitic action to acne pathophysiology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parasitic worm infections (Anthelmintic) — specific original_indications data not provided; based on known drug classification |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L5 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, mebendazole is a benzimidazole-class anthelmintic that inhibits β-tubulin polymerization and blocks glucose uptake in parasites, disrupting their energy metabolism and structural integrity.
There is no known biological relationship between this antiparasitic mechanism and the pathophysiology of acne, which involves follicular-sebaceous inflammation, C. acnes dysbiosis, sebum overproduction, and hyperkeratinization. No literature was found supporting an anti-inflammatory or antimicrobial effect of mebendazole relevant to acne treatment.
The TxGNN score of 99.20% reflects a strong model-generated association only, with no mechanistic explanation and no confirmatory clinical or preclinical evidence. This prediction should be treated as an unvalidated hypothesis rather than as supported evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7072899 | 1982 | Case Report | The American Journal of Tropical Medicine and Hygiene | Case report of human proliferative sparganosis presenting with acne-like nodular lesions; mentions "acne-like" only as a descriptive term for a parasitic skin lesion, not as evidence of therapeutic effect on acne. Relevance is unconfirmed (marked "pending"). |
New Zealand Market Information
Mebendazole is not currently marketed in New Zealand — no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package insert warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any S1 safety assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L5 (model prediction only) — there are no clinical trials, no mechanistically relevant literature, and the one identified publication only superficially mentions "acne-like" lesions in an unrelated parasitic disease case report. There is no plausible mechanistic link between mebendazole's antiparasitic action and acne pathophysiology.
To proceed, the following is needed:
- TFDA/regulatory package insert data (warnings and contraindications) — currently a Blocking gap (DG001)
- Verified mechanism of action data (DG001/DG002)
- Preclinical or in vitro studies specifically evaluating mebendazole in acne-relevant models (e.g., anti-inflammatory, anti-C. acnes, sebocyte activity)
- A targeted literature/clinical trial search specific to "mebendazole AND acne" to confirm the single retrieved reference is not a false positive
- Confirmation of relevance for the existing PMID 7072899 reference, since it does not currently support the proposed indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.